The outlook of companies tied to Sildenafil's past presents a complex investment scenario . While the initial boom generated substantial profits , generic copies have significantly diminished sales . Investing in associated pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving healthcare trends , and the